Drug intelligence / Profile preview

ensituximab

Development stage: Phase 2
Lead developer: Nascent Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Ensituximab is a chimeric monoclonal antibody developed for the treatment of cancer, specifically targeting gastrointestinal malignancies such as colorectal cancer. It binds to a tumor-associated variant of Mucin 5AC (MUC5AC), a mucin protein expressed on the surface of certain cancer cells but not on normal tissue. By binding to this target, ensituximab is designed to mediate immune responses against tumor cells through mechanisms such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The drug was developed by Nascent Biotech and has been evaluated in clinical trials for metastatic colorectal cancer.

Brand names: ensituximab
Other names: ensituximabNPC-1CNPC1CNPC 1CNEO-102NEO102NEO 102

Targets

MUC5AC (Mucin-5AC)

Beyond the preview

Go deeper on ensituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ensituximab.

Explore the full profile